Heritage Distilling to Implement 1-for-20 Reverse Stock Split-February 2024-www.financetom.com

Heritage Distilling to Implement 1-for-20 Reverse Stock Split

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Heritage Distilling to Implement 1-for-20 Reverse Stock Split

Oct 31, 2025 2:05 PM

04:52 PM EDT, 10/31/2025 (MT Newswires) -- Heritage Distilling ( IPST ) , doing business as IP Strategy, said late Friday that its board has approved a 1-for-20 reverse stock split to bring the company into compliance with Nasdaq's minimum bid price requirement.

The shares will begin trading on a split-adjusted basis on Nov. 5, the company said.

Shares were down over 13% during after-hours activity.

Previous page： Blackboxstocks Inc. Announces its Merger Target REalloys inks LOI for a 10-Year Offtake Agreement for 15% of Tanbreez Production with Critical Metals Corp. to Strengthen North American Rare Earth Inde Next page： Moderna Says Investigational Cancer Antigen Therapy Shows 'Promising' Early Data

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Blackboxstocks Inc. Announces its Merger Target REalloys inks LOI for a 10-Year Offtake Agreement for 15% of Tanbreez Production with Critical Metals Corp. to Strengthen North American Rare Earth Inde

Oct 13, 2025

The LOI is for a 10-year off-take agreement, which plans to provide REalloys with long-term heavy rare earth feedstock from Critical Metals Corp.’s Tanbreez Project in Greenland, one of the world’s most significant deposits. REalloys’ strategic partnership aligns with U.S. and allied priorities to build a fully independent North American mine-to-magnet supply chain. NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE)...

Moderna Says Investigational Cancer Antigen Therapy Shows 'Promising' Early Data

Oct 13, 2025

08:30 AM EDT, 10/13/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that its investigational cancer antigen therapy, mRNA-4359, in combination with pembrolizumab, has shown promising results in its phase 1/2 trial in certain Melanoma patients. The company said the combination therapy achieved a 24% objective response rate and a 60% disease control rate. Among a subgroup of patients...

Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation

Oct 13, 2025

08:30 AM EDT, 10/13/2025 (MT Newswires) -- Bicara Therapeutics ( BCAX ) said Monday that ficerafusp alfa in combination with pembrolizumab for the treatment of head and neck squamous cell carcinoma, or HNSCC, has received Breakthrough Therapy Designation from the US Food and Drug Administration. The designation shows recognition of human papillomavirus-negative HNSCC as a clear clinical indication within head...

CleanCore Solutions Congratulates House of Doge on Successful Go-Public Transaction and Provides Treasury Update

Oct 13, 2025

In collaboration with House of Doge and its strategic partners 21Shares and Robinhood, CleanCore will gain access to alpha-generating yield strategies designed to enhance treasury performance and long-term asset growth. House of Doge aims to accelerate Dogecoin’s adoption and real-world utility across commerce and paymentsHouse of Doge starts real-world tokenization initiatives, further accelerating the demand for dogecoin ...